ADAPTlate: Adj. Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+HR+/HER2- EBC
Weitere Informationen
BCP: Breast Cancer in Pregnancy Register Study
Weitere Informationen
HerediCaRe: Register zur Langzeit-Dokumentation von genetischen und klinischen Daten aus der Routineversorgung von Familien mit einer erblichen Belastung für Brust- und Eierstockkrebs
Weitere Informationen
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Weitere Informationen
LOBSTER: Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer
Weitere Informationen
DYNASTY-Breast02: A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET)
Weitere Informationen
FLAMINGO-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy
Weitere Informationen
BMBC (Brain Metastases in Breast Cancer Network Germany): Registerstudie für prospektiv und retrospektiv Daten zu Erkrankungsverläufen von Patientinnen mit Hirnmetastasen eines Mammakarzinoms
Weitere Informationen
